Blood test could spot cervical cancer spread early

NCT ID NCT02554565

Terminated Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at whether tumor DNA floating in the blood of cervical cancer patients can help detect early spread of the disease. Researchers took blood samples from 26 patients before, during, and after treatment. The goal was to see if this DNA test could find minimal metastatic disease sooner than usual methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a blood test that catches cervical cancer spread earlier than standard scans.
What could go wrong: The study was terminated early and was very small (26 people). It only looked for DNA in blood, not a treatment, so it may not change care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER

Contacts and locations

Locations

CHU Besançon

Besançon, 25000, France
Centre François Baclesse

Caen, 14076, France
Centre Jean Perrin

Clermont-Ferrand, 63000, France
Institut Curie

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.